Left ventricular noncompaction cardiomyopathy: What do we know?

Timothy E. Paterick, Thomas C. Gerber, Sala Ray Pradhan, Noralane Morey Lindor, A. Jamil Tajik

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Noncompaction is a rare and primary genetic cardiomyopathy affecting the left ventricle. The diagnosis is usually established by echocardiography, or, less frequently, by left ventriculography. Cardiac magnetic resonance and electrocardiography-gated multi-detector computed tomography are evolving noninvasive modalities to image cardiac structures, and have the utility to detect noncompacted myocardium. Estimates of the frequency and incidence of left ventricular noncompaction (LVNC) are limited because of the controversy over whether LVNC is a discrete disease entity. There is considerable overlap with dilated cardiomyopathy, apical hypertrophy, and hypertrophic cardiomyopathy. Symptoms, diagnosis, and prognosis are variable because of the heterogeneous nature of these diseases, making treatment often empirical and mimicking the treatment of other cardiomyopathies. However, there are management issues that should be addressed in each patient with LVNC, including genetic testing and family screening, the need for implantable cardioverter defibrillator placement, the role of anticoagulation in prevention of thromboembolic complications, and prescriptions/restrictions for implementation of physical activity.

Original languageEnglish (US)
Pages (from-to)92-99
Number of pages8
JournalReviews in Cardiovascular Medicine
Volume11
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Cardiomyopathies
Implantable Defibrillators
Hypertrophic Cardiomyopathy
Dilated Cardiomyopathy
Genetic Testing
Hypertrophy
Heart Ventricles
Prescriptions
Echocardiography
Myocardium
Electrocardiography
Magnetic Resonance Spectroscopy
Tomography
Exercise
Incidence
Therapeutics

Keywords

  • Automatic implantable cardioverter defibrillator
  • Cardiomyopathy
  • Hypertrabeculation
  • Noncompaction
  • Thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Left ventricular noncompaction cardiomyopathy : What do we know? / Paterick, Timothy E.; Gerber, Thomas C.; Pradhan, Sala Ray; Lindor, Noralane Morey; Jamil Tajik, A.

In: Reviews in Cardiovascular Medicine, Vol. 11, No. 2, 03.2010, p. 92-99.

Research output: Contribution to journalArticle

Paterick, TE, Gerber, TC, Pradhan, SR, Lindor, NM & Jamil Tajik, A 2010, 'Left ventricular noncompaction cardiomyopathy: What do we know?', Reviews in Cardiovascular Medicine, vol. 11, no. 2, pp. 92-99. https://doi.org/10.3909/ricm0531
Paterick, Timothy E. ; Gerber, Thomas C. ; Pradhan, Sala Ray ; Lindor, Noralane Morey ; Jamil Tajik, A. / Left ventricular noncompaction cardiomyopathy : What do we know?. In: Reviews in Cardiovascular Medicine. 2010 ; Vol. 11, No. 2. pp. 92-99.
@article{3fc77f9252494aa9bebc6efba4cc63f6,
title = "Left ventricular noncompaction cardiomyopathy: What do we know?",
abstract = "Noncompaction is a rare and primary genetic cardiomyopathy affecting the left ventricle. The diagnosis is usually established by echocardiography, or, less frequently, by left ventriculography. Cardiac magnetic resonance and electrocardiography-gated multi-detector computed tomography are evolving noninvasive modalities to image cardiac structures, and have the utility to detect noncompacted myocardium. Estimates of the frequency and incidence of left ventricular noncompaction (LVNC) are limited because of the controversy over whether LVNC is a discrete disease entity. There is considerable overlap with dilated cardiomyopathy, apical hypertrophy, and hypertrophic cardiomyopathy. Symptoms, diagnosis, and prognosis are variable because of the heterogeneous nature of these diseases, making treatment often empirical and mimicking the treatment of other cardiomyopathies. However, there are management issues that should be addressed in each patient with LVNC, including genetic testing and family screening, the need for implantable cardioverter defibrillator placement, the role of anticoagulation in prevention of thromboembolic complications, and prescriptions/restrictions for implementation of physical activity.",
keywords = "Automatic implantable cardioverter defibrillator, Cardiomyopathy, Hypertrabeculation, Noncompaction, Thromboembolism",
author = "Paterick, {Timothy E.} and Gerber, {Thomas C.} and Pradhan, {Sala Ray} and Lindor, {Noralane Morey} and {Jamil Tajik}, A.",
year = "2010",
month = "3",
doi = "10.3909/ricm0531",
language = "English (US)",
volume = "11",
pages = "92--99",
journal = "Reviews in Cardiovascular Medicine",
issn = "1530-6550",
publisher = "MedReviews LLC",
number = "2",

}

TY - JOUR

T1 - Left ventricular noncompaction cardiomyopathy

T2 - What do we know?

AU - Paterick, Timothy E.

AU - Gerber, Thomas C.

AU - Pradhan, Sala Ray

AU - Lindor, Noralane Morey

AU - Jamil Tajik, A.

PY - 2010/3

Y1 - 2010/3

N2 - Noncompaction is a rare and primary genetic cardiomyopathy affecting the left ventricle. The diagnosis is usually established by echocardiography, or, less frequently, by left ventriculography. Cardiac magnetic resonance and electrocardiography-gated multi-detector computed tomography are evolving noninvasive modalities to image cardiac structures, and have the utility to detect noncompacted myocardium. Estimates of the frequency and incidence of left ventricular noncompaction (LVNC) are limited because of the controversy over whether LVNC is a discrete disease entity. There is considerable overlap with dilated cardiomyopathy, apical hypertrophy, and hypertrophic cardiomyopathy. Symptoms, diagnosis, and prognosis are variable because of the heterogeneous nature of these diseases, making treatment often empirical and mimicking the treatment of other cardiomyopathies. However, there are management issues that should be addressed in each patient with LVNC, including genetic testing and family screening, the need for implantable cardioverter defibrillator placement, the role of anticoagulation in prevention of thromboembolic complications, and prescriptions/restrictions for implementation of physical activity.

AB - Noncompaction is a rare and primary genetic cardiomyopathy affecting the left ventricle. The diagnosis is usually established by echocardiography, or, less frequently, by left ventriculography. Cardiac magnetic resonance and electrocardiography-gated multi-detector computed tomography are evolving noninvasive modalities to image cardiac structures, and have the utility to detect noncompacted myocardium. Estimates of the frequency and incidence of left ventricular noncompaction (LVNC) are limited because of the controversy over whether LVNC is a discrete disease entity. There is considerable overlap with dilated cardiomyopathy, apical hypertrophy, and hypertrophic cardiomyopathy. Symptoms, diagnosis, and prognosis are variable because of the heterogeneous nature of these diseases, making treatment often empirical and mimicking the treatment of other cardiomyopathies. However, there are management issues that should be addressed in each patient with LVNC, including genetic testing and family screening, the need for implantable cardioverter defibrillator placement, the role of anticoagulation in prevention of thromboembolic complications, and prescriptions/restrictions for implementation of physical activity.

KW - Automatic implantable cardioverter defibrillator

KW - Cardiomyopathy

KW - Hypertrabeculation

KW - Noncompaction

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=77957335819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957335819&partnerID=8YFLogxK

U2 - 10.3909/ricm0531

DO - 10.3909/ricm0531

M3 - Article

C2 - 20700091

AN - SCOPUS:77957335819

VL - 11

SP - 92

EP - 99

JO - Reviews in Cardiovascular Medicine

JF - Reviews in Cardiovascular Medicine

SN - 1530-6550

IS - 2

ER -